Sale on Ophthalmic Equipment - Starting from 16 November!
GE HealthCare raises its 2026 earnings outlook after reporting $5.5bn in Q3 revenue, driven by strong pharmaceutical diagnostics growth and its planned $945m SOFIE Biosciences acquisition.
GE HealthCare has raised its 2026 earnings forecast after reporting $5.5bn in third-quarter revenue, up 7.2% year on year. Strong growth in pharmaceutical diagnostics (PDx) drove the results, along with higher revenue across its imaging and patient care businesses.
The company now expects adjusted earnings per share of $4.95 to $5.05 for 2026, compared with its previous guidance of $4.80 to $5.00. The revised outlook follows results released on 28 October 2026.
Pharmaceutical Diagnostics Leads Quarterly Growth
GE HealthCare's PDx division recorded the strongest annual revenue growth among its three main operating segments.
Advanced Imaging Solutions (AIS) remained the largest contributor, generating approximately $3.8bn. PDx recorded $846m, while Patient Care Solutions delivered $793m.
The segments reported the following year-on-year growth:
Pharmaceutical Diagnostics: 13%
Patient Care Solutions: 8.5%
Advanced Imaging Solutions: 6.1%
PDx includes contrast media and radiopharmaceutical agents used in diagnostic procedures. Its portfolio includes Flyrcado, a radiopharmaceutical used for myocardial perfusion imaging.
The US Food and Drug Administration approved Flyrcado in September 2024. SOFIE Biosciences manufactures the product, and GE HealthCare has agreed to acquire it.
Earlier in October, GE HealthCare announced a $945m agreement to acquire SOFIE Biosciences, a US contract manufacturer specialising in radiopharmaceutical products.
The transaction is expected to close in the first half of 2027, subject to regulatory approvals and other customary conditions.
SOFIE operates a US network of 15 contract manufacturing sites alongside a contract development and manufacturing facility focused on theranostics.
GE HealthCare expects the acquisition to expand manufacturing capacity and improve distribution capabilities for positron emission tomography (PET) imaging agents.
The agreement also gives the company an opportunity to expand its participation in radiopharmaceutical markets beyond its existing product range.
CEO Highlights Recurring Diagnostics Revenue
During the quarterly earnings call, GE HealthCare president and CEO Peter Arduini said PDx had maintained at least high-single-digit growth for five consecutive quarters.
He also outlined the company's continued investment in production infrastructure and supply chain capacity.
“We are investing in strengthening our supply chain and manufacturing capabilities and expanding where we can create value,” Arduini said.
The division benefits from recurring demand because diagnostic imaging procedures require individual doses of contrast media or radiopharmaceutical agents.
This links PDx revenue to patient volumes and the number of imaging procedures performed.
The planned acquisition also raises questions about GE HealthCare's commercial relationship with Lantheus, another participant in the nuclear imaging market.
Although the companies compete in radiopharmaceutical imaging, they also maintain licensing and manufacturing connections.
Lantheus developed Flyrcado before GE HealthCare obtained a licence in 2017. Lantheus continues to receive royalties from US sales of the product.
SOFIE also manufactures Neuraceq and Pylarify for Lantheus. Together, those two products generated more than $1bn in sales during 2025.
GlobalData analysts have pointed to the commercial complexity that could follow the transaction. Once completed, GE HealthCare would manufacture important products for a competitor that already benefits financially from Flyrcado sales.
Both companies would therefore retain commercial interests connected to each other's pharmaceutical imaging portfolios.
GE HealthCare's quarterly performance reflects growth across equipment sales, patient monitoring and pharmaceutical diagnostics.
The SOFIE acquisition could also strengthen the company's control over radiopharmaceutical manufacturing and supply, particularly in the US PET imaging market.
For healthcare procurement teams, these developments provide further context on changes across the wider diagnostic imaging industry. Medigear.uk also covers developments in medical imaging technology, including equipment and diagnostic workflows.
Rising PDx revenue and manufacturing investment put radiopharmaceutical supply at the centre of GE HealthCare's growth plans.
Source: Medical Device Network
Tell us the model and destination — our sourcing team will respond within one business day.

The Zimmer Monogram robot is now with US regulators. Zimmer Biomet has filed a 510(k) submission for…

The Abbott Encantor trial has begun. Abbott said on Thursday that it has started the VOYAGER CE clin…

Johnson & Johnson (J&J) said on Thursday that a Houston hospital will be the first to instal…
Approvals, trials, recalls and market moves — the essentials for procurement and clinical teams.